These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38782175)

  • 41. UK-Wide Multicenter Evaluation of Second-line Therapies in Primary Biliary Cholangitis.
    Abbas N; Culver EL; Thorburn D; Halliday N; Crothers H; Dyson JK; Phaw A; Aspinall R; Khakoo SI; Kallis Y; Smith B; Patanwala I; McCune A; Chimakurthi CR; Hegade V; Orrell M; Jones R; Mells G; Thain C; Thain RM; Jones D; Hirschfield G; Trivedi PJ
    Clin Gastroenterol Hepatol; 2023 Jun; 21(6):1561-1570.e13. PubMed ID: 35961518
    [TBL] [Abstract][Full Text] [Related]  

  • 42. RANK/RANKL Acts as a Protective Factor by Targeting Cholangiocytes in Primary Biliary Cholangitis.
    Hao YL; Bian ZL; Ju LL; Liu Y; Qin G
    Dig Dis Sci; 2020 Feb; 65(2):470-479. PubMed ID: 31377883
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis.
    Harms MH; de Veer RC; Lammers WJ; Corpechot C; Thorburn D; Janssen HLA; Lindor KD; Trivedi PJ; Hirschfield GM; Pares A; Floreani A; Mayo MJ; Invernizzi P; Battezzati PM; Nevens F; Ponsioen CY; Mason AL; Kowdley KV; Hansen BE; Buuren HRV; van der Meer AJ
    Gut; 2020 Aug; 69(8):1502-1509. PubMed ID: 31843787
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The relationship between disease activity and UDCA response criteria in primary biliary cholangitis: A cohort study.
    Jones DEJ; Wetten A; Barron-Millar B; Ogle L; Mells G; Flack S; Sandford R; Kirby J; Palmer J; Brotherston S; Jopson L; Brain J; Smith GR; Rushton S; Jones R; Rushbrook S; Thorburn D; Ryder SD; Hirschfield G; ; Dyson JK
    EBioMedicine; 2022 Jun; 80():104068. PubMed ID: 35609437
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy.
    Lammers WJ; Hirschfield GM; Corpechot C; Nevens F; Lindor KD; Janssen HL; Floreani A; Ponsioen CY; Mayo MJ; Invernizzi P; Battezzati PM; Parés A; Burroughs AK; Mason AL; Kowdley KV; Kumagi T; Harms MH; Trivedi PJ; Poupon R; Cheung A; Lleo A; Caballeria L; Hansen BE; van Buuren HR;
    Gastroenterology; 2015 Dec; 149(7):1804-1812.e4. PubMed ID: 26261009
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Response to Ursodeoxycholic Acid May Be Assessed Earlier to Allow Second-Line Therapy in Patients with Unresponsive Primary Biliary Cholangitis.
    Cançado GGL; Couto CA; Terrabuio DRB; Cançado ELR; Villela-Nogueira CA; Ferraz MLG; Braga MH; Nardelli MJ; Faria LC; de Faria Gomes NM; Oliveira EMG; Rotman V; Oliveira MB; da Cunha SMCF; Cunha-Silva M; Mendes LSC; Ivantes CAP; Codes L; de Almeida E Borges VF; de Lima Pace FH; Pessoa MG; Guedes LV; Signorelli IV; Coral GP; Levy C; Bittencourt PL;
    Dig Dis Sci; 2023 Feb; 68(2):514-520. PubMed ID: 35989386
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Fibrates for Primary Biliary Cholangitis: What's All the Hype?
    Levy C
    Ann Hepatol; 2017; 16(5):704-706. PubMed ID: 28809729
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Primary biliary cholangitis with normal alkaline phosphatase: A neglected clinical entity challenging current guidelines.
    Terziroli Beretta-Piccoli B; Stirnimann G; Mertens J; Semela D; Zen Y; Mazzucchelli L; Voreck A; Kolbus N; Merlo E; Di Bartolomeo C; Messina P; Cerny A; Costantini S; Vergani D; Mieli-Vergani G;
    J Autoimmun; 2021 Jan; 116():102578. PubMed ID: 33229138
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and safety of obeticholic acid in liver disease-A systematic review and meta-analysis.
    Kulkarni AV; Tevethia HV; Arab JP; Candia R; Premkumar M; Kumar P; Sharma M; Reddy DN; Padaki NR
    Clin Res Hepatol Gastroenterol; 2021 May; 45(3):101675. PubMed ID: 33722778
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis.
    Schramm C; Wedemeyer H; Mason A; Hirschfield GM; Levy C; Kowdley KV; Milkiewicz P; Janczewska E; Malova ES; Sanni J; Koo P; Chen J; Choudhury S; Klickstein LB; Badman MK; Jones D
    JHEP Rep; 2022 Nov; 4(11):100544. PubMed ID: 36267872
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Investigational farnesoid X receptor agonists for the treatment of primary biliary cholangitis.
    Akepati PR; Gochanour EM
    Expert Opin Investig Drugs; 2024 Jun; 33(6):627-638. PubMed ID: 38676426
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Emerging drugs for the treatment of primary biliary cholangitis.
    Phaw NA; Dyson JK; Jones D
    Expert Opin Emerg Drugs; 2020 Jun; 25(2):101-112. PubMed ID: 32253941
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Diagnosis and Treatment of Primary Biliary Cholangitis].
    Kim KA
    Korean J Gastroenterol; 2023 Feb; 81(2):86-90. PubMed ID: 36824036
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment response to ursodeoxycholic acid in primary biliary cholangitis: A systematic review and meta-analysis.
    Gazda J; Drazilova S; Gazda M; Janicko M; Koky T; Macej M; Carbone M; Jarcuska P
    Dig Liver Dis; 2023 Oct; 55(10):1318-1327. PubMed ID: 36593158
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Combination therapy of obeticholic acid and ursodeoxycholic acid in patients with primary biliary cholangitis who respond incompletely to ursodeoxycholic acid: a systematic review.
    Li X; Liao M; Pan Q; Xie Q; Yang H; Peng Y; Li Q; Qu J; Chai J
    Eur J Gastroenterol Hepatol; 2020 Sep; 32(9):1116-1122. PubMed ID: 32649329
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Optimizing biochemical markers as endpoints for clinical trials in primary biliary cirrhosis.
    Momah N; Silveira MG; Jorgensen R; Sinakos E; Lindor KD
    Liver Int; 2012 May; 32(5):790-5. PubMed ID: 22136310
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Primary biliary cholangitis: treatment.
    Cazzagon N; Floreani A
    Curr Opin Gastroenterol; 2021 Mar; 37(2):99-104. PubMed ID: 33492001
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-Term Obeticholic Acid Therapy Improves Histological Endpoints in Patients With Primary Biliary Cholangitis.
    Bowlus CL; Pockros PJ; Kremer AE; Parés A; Forman LM; Drenth JPH; Ryder SD; Terracciano L; Jin Y; Liberman A; Pencek R; Iloeje U; MacConell L; Bedossa P
    Clin Gastroenterol Hepatol; 2020 May; 18(5):1170-1178.e6. PubMed ID: 31606455
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Influence factors and a predictive scoring model for measuring the biochemical response of primary biliary cholangitis to ursodeoxycholic acid treatment.
    Chen J; Xue D; Gao F; Tao L; Li Y; Zhang Q; Wang R; Sun L; Yang X; Liu Y; Zhu B; Niu S; Wang X
    Eur J Gastroenterol Hepatol; 2018 Nov; 30(11):1352-1360. PubMed ID: 29889683
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Improving prognosis in primary biliary cholangitis - Therapeutic options and strategy.
    Harms MH; van Buuren HR; van der Meer AJ
    Best Pract Res Clin Gastroenterol; 2018; 34-35():85-94. PubMed ID: 30343714
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.